Role of serum interleukin 6, albumin and C-reactive protein in COPD patients

Tanaffos

Volumn 14, Issue 2, 2015, Pages 134-140

  Emami Ardestani, Mohammad ^a   Zaerin, Omid ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Albumin; C Reactive protein; Chronic obstructive pulmonary disease; Interleukin 6

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; INTERLEUKIN 6;

ADULT; AGE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; SMOKING; SPIROMETRY;

EID: 84942848329     PISSN: 17350344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Antó JM, Vermeire P, Vestbo J, Sunyer J. Epidemiology of chronic obstructive pulmonary disease. Eur Respir J 2001; 17 (5): 982-94.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349 (9064): 1498-504.
3. Garrod R, Marshall J, Barley E, Fredericks S, Hagan G. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2007; 16 (4): 236-40.
4. Longo D, Fauci A, Kasper D, Hauser S. Harrison's Principles of Internal Medicine 18th edition. McGraw-Hill Professional, 2011; part 11, section 2, chapter 260.
5. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: molecular and cellular mechanisms. Eur Respir J 2003; 22 (4): 672-88.
6. Shapiro SD. Evolving concepts in the pathogenesis of chronic obstructive pulmonary disease. Clin Chest Med 2000; 21 (4): 621-32.
7. Tangedal S, Aanerud M, Persson LJ, Brokstad KA, Bakke PS, Eagan TM. Comparison of inflammatory markers in induced and spontaneous sputum in a cohort of COPD patients. Respir Res 2014; 15: 138.
8. Chung KF, Adcock IM. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008; 31 (6): 1334-56.
9. Barnes PJ. Emerging pharmacotherapies for COPD. Chest 2008; 134 (6): 1278-86.
10. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61 (1): 17-22.
11. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 174 (8): 867-74.
12. Ferrari R, Tanni SE, Caram LM, Corrêa C, Corrêa CR, Godoy I. Three-year follow-up of Interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease. Respir Res 2013; 14: 24.
13. Banh L. Serum proteins as markers of nutrition: what are we treating? Practical Gastroenterology 2006; 30(10): 46.
14. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Available at: www. goldcopd.com. Accessed July 6, 2006.
15. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995; 152 (5 Pt 2): S77-121.
16. Risby TH. Further discussion on breath condensate analysis. Am J Respir Crit Care Med 2003; 167 (10): 1301-2.
17. Sevenoaks MJ, Stockley RA. Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity--a common inflammatory phenotype? Respir Res 2006; 7: 70.
18. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, et al. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013; 68 (7): 670-6.
19. Wouters EF, Groenewegen KH, Dentener MA, Vernooy JH. Systemic inflammation in chronic obstructive pulmonary disease: the role of exacerbations. Proc Am Thorac Soc 2007; 4 (8): 626-34.
20. Gan WQ, Man SF, Senthilselvan A, Sin DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 2004; 59 (7): 574-80.
21. Kishimoto T. The biology of interleukin-6. Blood 1989; 74 (1): 1-10.
22. Garrod R, Marshall J, Barley E, Fredericks S, Hagan G. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J 2007; 16 (4): 236-40.
23. Kolsum U, Roy K, Starkey C, Borrill Z, Truman N, Vestbo J, et al. The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. Int J Chron Obstruct Pulmon Dis 2009; 4: 149-56.
24. Eid AA, Ionescu AA, Nixon LS, Lewis-Jenkins V, Matthews SB, Griffiths TL, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164 (8 Pt 1): 1414-8.
25. Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006; 61 (1): 23-8.
26. Pinto-Plata V, Casanova C, Müllerova H, de Torres JP, Corado H, Varo N, et al. Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD. Respir Res 2012; 13: 71.
27. Agustí A, Edwards LD, Rennard SI, MacNee W, Tal-Singer R, Miller BE, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012; 7 (5): e37483.
28. Celli BR, Locantore N, Yates J, Tal-Singer R, Miller BE, Bakke P, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185 (10): 1065-72.
29. Mannino DM, Tal-Singer R2, Lomas DA3, Vestbo J4, Graham Barr R5, Tetzlaff K6, et al. Plasma Fibrinogen as a Biomarker for Mortality and Hospitalized Exacerbations in People with COPD. Chronic Obstr Pulm Dis (Miami) 2015; 2 (1): 23-34.
30. Rincon M. Interleukin-6: from an inflammatory marker to a target for inflammatory diseases. Trends Immunol 2012; 33 (11): 571-7.
31. Kolsum U, Roy K, Starkey C, Borrill Z, Truman N, Vestbo J, et al. The repeatability of interleukin-6, tumor necrosis factor-alpha, and C-reactive protein in COPD patients over one year. Int J Chron Obstruct Pulmon Dis 2009; 4: 149-56.
32. Mehrotra N, Freire AX, Bauer DC, Harris TB, Newman AB, Kritchevsky SB, et al. Predictors of mortality in elderly subjects with obstructive airway disease: the PILE score. Ann Epidemiol 2010; 20 (3): 223-32.
33. Brinkley TE, Leng X, Miller ME, Kitzman DW, Pahor M, Berry MJ, et al. Chronic inflammation is associated with low physical function in older adults across multiple comorbidities. J Gerontol A Biol Sci Med Sci 2009; 64 (4): 455-61.
34. de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, Córdoba-Lanús E, Muros de Fuentes M, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008; 133 (6): 1336-43.
35. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 2006; 61 (10): 849-53.
36. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 175 (3): 250-5.